IDBS’ E-WorkBook for Biology Selected to Provide GLP Data Management for BSL BIOSERVICE
News Apr 07, 2009
IDBS has announced that BSL BIOSERVICE Scientific Laboratories GmbH have purchased E-Workbook, and its Biology extension, BioBook, for use in their GLP-regulated in-vivo department, where it will capture, search, protect and share high value research and preclinical data on behalf of a broad spectrum of international clients.
BSL BIOSERVICE is a contract research organization. As a member of the Eurofin group, BSL BIOSERVICE provides testing services across the EU and is listed by the World Health Organization (WHO) to perform bioassays.
Wolfram Riedel, CEO of BSL BIOSERVICE commented, “We are excited about our new business relationship with IDBS.” He continued, “In addition to needing the right tools to handle complex biological data, we also needed a partner who understood the demanding requirements of GLP and 21 CFR part 11 compliance.”
Neil Kipling, founder and CEO of IDBS said, “E-WorkBook for biology (BioBook) has now become the solution of choice for the capture, analysis and storage of preclinical data; its increasing selection for use in regulated (GxP) environments is testament to its security, robustness and scalability. We are pleased to add BIOSERVICE to our growing list of international E-WorkBook clients in the GLP area. IDBS will continue to invest in innovation and delivering forward-looking technologies to the worldwide R&D market.”
Towards Personalized Medicine: One Type of Data is Not EnoughNews
To understand the biology of diseased organs researchers use different types of molecular data. One of the biggest computational challenges at the moment is integrating these multiple data types. A new computational method jointly analyses different types of molecular data and disentangles the sources of disease variability to guide personalized treatment.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE